Sitavig®

Onxeo Divests Two Non-Core Products in Oral Pathologies to Vectans Pharma

Transaction confirms Onxeo’s strategic focus on innovative orphan oncology drugs Paris (France), July 31, 2017 – 05:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced the sale of two historical products…read more →

Cipher Pharmaceuticals acquires INNOCUTIS Holdings, licensee of Sitavig® in the USA – Cipher Pharmaceuticals erhverver INNOCUTIS Holdings, som er kommerciel samarbejdspartner for Sitavig® i USA

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced Cipher Pharmaceuticals’ (NASDAQ: CPHR) acquisition of INNOCUTIS Holdings LLC, the licensee of Sitavig® in the USA. Cipher Pharmaceuticals (“Cipher”) is a rapidly growing specialty pharmaceutical dermatology company with a goal of becoming the most customer-centric dermatology company in North America….read more →

BioAlliance Pharma announces the launch of Sitavig® in the United States by its partner Innocutis and the granting of a new U.S. Sitavig® patent

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced the launch of Sitavig® (acyclovir Lauriad®) in the United States by its commercial partner, Innocutis Holdings LLC, and the granting of a new U.S. Sitavig® patent by the United States Patent and Trademark Office. A few weeks after…read more →

Execution of a license agreement with EMS for Sitavig® in Brazil

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced the signature of a license agreement for Sitavig® (acyclovir Lauriad®) with EMS S/A for commercialization rights in Brazil. Approved in the treatment of recurrent labial herpes, Sitavig® is already registered in the United States and in 10 major…read more →

Quarterly information as of March 31, 2014

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today published a summary of the key events of the first quarter of 2014, as well as its consolidated revenues for the quarter. Key orphan oncology programs Validive® and Livatag® have successfully reached important milestones during the first quarter of…read more →

BioAlliance Pharma signs a new licensing agreement with Daewoong Pharmaceutical Co., Ltd. for Sitavig®’s commercialization in South Korea

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announces an exclusive supply and license agreement for Sitavig® (Acyclovir Lauriad®) with Daewoong Pharmaceutical Co., Ltd. for commercialization rights in South Korea. Moreover, Daewoong will be in charge of registering Sitavig® in South Korea. Under this agreement, BioAlliance Pharma…read more →

Sitavig® Licensing Strategy: Execution of licensing agreement with Innocutis for North America and Positive opinion from French and German Health Authorities for Marketing Authorization

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products, announced major advancements in the licensing strategy of Sitavig® (acyclovir Lauriad®) for the treatment of recurrent labial herpes, with the execution of a licensing agreement with Innocutis Holding LLC to commercialize Sitavig® in North America. In Europe, the Company received a positive…read more →

Quarterly information as of September 30, 2013

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of Orphan Oncology Products and to Supportive Care Products, today published the major key milestones achieved during the third quarter of 2013. July was marked by a successful capital increase which enabled the Company to raise a net amount of €8.4 million and showed strong support…read more →

BioAlliance Pharma Strengthens Sitavig® Patent Protection with New U.S. and South Korean issued Patents

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company dedicated to the development of orphan oncology and to supportive care products, announces the issuance of two new patents for Sitavig® (acyclovir mucoadhesive tablet) by the U.S. and South Korean patent offices. Sitavig® is approved in the U.S. and eight European countries (Sweden, the U.K., Spain, Italy, Denmark, Finland, Norway…read more →

Key milestones and consolidated accounts First semester 2013

Grant of the Marketing Authorization for Sitavig® in the US Strong achievements in clinical trials with Livatag® (phase III) and Validive® (phase II) Significant reinforcement of cash reserves thanks to the capital increase of July 2013 BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, today…read more →

BioAlliance Pharma expands and strengthens its industrial property assets with two patent grants

(Français) BioAlliance Pharma SA (Euronext Paris – BIO), Société d’innovation dédiée aux produits orphelins en cancérologie et aux produits de spécialité, annonce la délivrance de deux brevets par les Offices américain et japonais pour ses deux médicaments Oravig® (miconazole dans le traitement de la candidose oropharyngée) et Sitavig® (acyclovir dans le traitement de l’herpès labial).

BioAlliance Pharma’s Sitavig® receives Market Authorization in the US for the treatment of Herpes Labialis

Second BioAlliance Pharma drug registered in the US An effective and innovative medicine for the treatment of a frequent infection, recurrent Herpes labialis in adults BioAlliance Pharma SA (Euronext Paris – BIO), today announced the receipt of marketing authorization from the U.S. Food and Drug Administration (FDA) for Sitavig® in the treatment of recurring Herpes labialis, marking the successful conclusion…read more →

Bioalliance Pharma updates on major achievements of 2012 and publishes its 2012 consolidated financial statements and income for Q1 2013

Successful key milestones reached on all orphan oncology clinical programs First registration of Sitavig granted in European countries Oravig licensing agreement signed for US Income growth and operating costs under control. Paris, April 15, 2013 – BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company dedicated to the development of orphan oncology products and to supportive care products today…read more →

BioAlliance Pharma signs a collaborative agreement with one of the worldwide leaders in vaccines for a vaccine application of its patented Lauriad® mucoadhesive technology

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces a collaboration agreement with one of the world leading vaccine companies to develop a vaccine application of its Lauriad® mucoadhesive technology. The terms of this agreement are not disclosed at this time. This research program aims…read more →